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Running title: eGFR and prognosis after stroke 
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Abstract 
Background: Relationship of estimated glomerular filtration rate (eGFR) with complications 
after stroke has not been fully characterized for entire clinical spectrum of eGFR and for the 
fluctuation in eGFR during hospital stay.  
Methods: Data from the Norfolk and Norwich Stroke Registry recorded between January 
2003 and April 2015 was analysed. eGFR was categorized into six clinically relevant 
categories as per Kidney Disease Improving Global Outcomes guidelines. Change in eGFR 
during acute admission was categorized into: within 5% change (ref.), 5-20% decline, >20% 
decline, 5-20% increase and >20% increase. All-cause mortality, recurrent stroke, incident 
myocardial infarction, prolonged hospital stay and stroke disability at discharge were 
outcomes of interest.   
Results: 10,329 stroke patients  (mean age 77.8 years) were followed for a mean of 2.9 years 
(30,126 person years). Multivariable adjusted hazard ratios (HRs) (95%CI) for all-cause 
mortality were 0.91 (0.80-1.04), 0.96 (0.83-1.11), 1.23 (1.06-1.43), 1.54 (1.31-1.82) and 2.38 
(1.91-2.97) for eGFR levels 60-89, 45-59, 30-44, 15-29 and <15 respectively, compared to 
eGFR ≥90 mL/min/1.73m
2
. The HR (95%CI) for eGFR change were 1.56 (1.36-1.79), 1.17 
(1.05-1.30), 1.47 (1.32-1.62) and 1.71 (1.55-1.88) for >20% decline, 5-20% decline, 5-20% 
increase and >20 % increase, respectively, compared to change within 5%. Results were 
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Conclusions: Stroke patients with eGFR <45 mL/min/1.73m
2
 at hospital admission and > 5% 
decline or increase in eGFR during hospital stay were at substantially high risk of poor 
outcomes, particularly all-cause mortality, myocardial infarction, prolonged hospital stay and 
disability at discharge.  
 
Introduction 
More than a third of stroke patients have low estimated glomerular filtration rate (eGFR) 
(<60 mL/min/1.73m
2
) at hospital admission [1,2]. Previous studies suggested that stroke 
patients with low eGFR are at increased risk of poor clinical outcomes including death, 
prolonged hospital stay and disability after hospital discharge [3-5]. However, there are few 
studies assessing the association between eGFR divided into all clinically relevant categories 
and stroke outcomes. Understanding the size and shape of the association across all clinically 
relevant categories of eGFR is not only essential for clinical decision making but is also vital 
in helping patients and their families understand the course of the disease. In addition, in 
previous studies eGFR was only assessed at single time point on admission, thus whether 
change in eGFR during hospital stay could be a prognostic factor in stroke patients is 
virtually unknown.  
This study aimed to examine the association of eGFR categorised as per recent 
Kidney Disease Improving Global Outcomes (KDIGO) guidelines [6] with complications 
including all-cause mortality, stroke recurrence, incident myocardial infarction, prolonged 
hospital stay and disability at hospital discharge in stroke patients. In addition, we examined 
the association between change in eGFR during hospital stay and aforementioned outcomes 
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Materials and Methods 
Sample population 
Data of unselected consecutive patients from the Norfolk and Norwich Stroke Registry at the 
Norfolk and Norwich University Hospital which serves a population of~750,000 were used. 
Details of data collection has been described previously [7]. Briefly, data was originally 
obtained in paper-form which was reviewed and entered onto the register database by the 
hospital stroke data team and was linked with electronic records [8]. Newcastle and Tyneside 
National Health Service (NHS) Research Ethics Committee delivered ethical approval 
(12/NE/0170) and the Steering Committee of the Norfolk and Norwich Stroke Register 
approved the study protocol. Because Norfolk and Norwich Stroke registry was a research 
database of all consecutive patients, individual patients were not required to provide written 
informed consent. 
 Between January 2003 and April 30, 2015, 10,683 cases of ischemic or hemorrhagic 
stroke patients (age ≥18 years) were admitted to the hospital. Because biochemistry data were 
electronically available only after January 2003, patients were included from the beginning of 
2003. Patients with missing information on variable needed to obtain eGFR i.e. serum 
creatinine were excluded (n=354). Complete information was available on comorbidities 
including diabetes, hypertension, heart failure, hypercholesterolemia, coronary heart disease, 
atrial fibrillation, and pneumonia. After exclusion, 10,329 stroke patients were available for 
analysis. 
Estimated glomerular filtration rate 
Two serum creatinine measurements were obtained, once on hospital admission and another 
near to hospital discharge (alive or dead) using the Jaffe method and standardized to isotype 
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Kidney Disease-Epidemiology collaboration equation [9]. Chronic Kidney Disease-
Epidemiology collaboration equation employ separate equation for subjects of non-white 
origin. We lacked data on race/ethnicity. However, non-white ethnicity makes less than 2% 
of Norwich population. Thus, eGFR misclassification due to lack of information on 
race/ethnicity is likely to be minimal [10]. As per KDIGO guidelines [6], admission eGFR 





Specialist stroke nurses or doctors collected information on demographic factors including 
age and sex, and information on medical history including history of stroke, type of stroke 
(ischemic or hemorrhagic), pre-stroke modified Rankin Score (mRS) (modified by the UK 
transient ischemic attack investigators) [11] (0-5), and Oxfordshire Community Stroke 
Project (OCSP) Classification. Co-morbidities including diabetes, hypertension, 
dyslipidaemia, heart failure, atrial fibrillation, coronary heart disease and pneumonia were 
obtained through linking registry data to electronic health record.  
Outcome(s) 
All-cause mortality, recurrent stroke, incident myocardial infarction, prolonged hospital stay, 
and stroke disability were selected as outcomes for the study purpose. Mortality status was 
recorded at discharge to record in-hospital mortality. Linkage with the Office of National 
Statistics was established in UK National Health Service order to obtain follow-up mortality 
data. Information on recurrent stroke and post stroke incidence of myocardial infarction was 
obtained through electronic record linkage. Recurrent stroke cases were additionally 
identified by assessing repeated admission(s) of a patient for stroke recorded in the registry. 
Prolonged hospital stay was defined as hospital stay longer than median days of hospital stay. 
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classified into three groups: mild (0-1), moderate (2-3) and severe (4-6). For all-cause 
mortality, recurrent stroke and myocardial infarction, patients were followed until May 30, 
2015 so as to have minimal follow up of one month. For clinical relevance, the risk of <30, 
30-365 and >365 day mortality was examined separately in addition to overall mortality over 
the whole follow up.  
Statistical analysis 
Cox proportional hazards regression analysis was performed to estimate hazard ratios (HRs) 
for the association between eGFR categories (with eGFR ≥90 mL/min/1.73 m
2
 as the 
reference group) and all-cause mortality. Competing risk regression analysis [12] was 
performed to calculate sub-distribution HRs for recurrent stroke and incident myocardial 
infarction, considering all-cause mortality as a competing risk. Logistic regression analyses 
was performed for prolonged hospital stay and Ordinal logistic regression for stroke disability 
at discharge. Since death may skew analyses for prolonged hospital stay, this analyses was 
performed for patients that were alive at discharge. Multivariable models were constructed to 
adjust for potential confounders. Model 1 was adjusted for age and sex. Model 2 was 
additionally adjusted for previous stroke, pre-stroke mRS, stroke type, stroke severity (using 
OCSP classification), and the comorbid conditions listed above. Test of models assumptions 
indicated that our models fit the data well. 
In addition, we explored the association between eGFR distribution and outcomes by 
dividing eGFR into groups spanning 10 mL/min/1.73 m
2
: <20, 20-29, 30-39, 40–49, 50–59, 
60–69, 70–79, 80–89, 90-99 (reference), 100-109 and ≥110 mL/min/1.73 m
2
. There were 
fewer incident myocardial infarction and recurrent stroke due to multiple groups. Thus, a 
combined end point of myocardial infarction, recurrent stroke and all-cause mortality was 










This article is protected by copyright. All rights reserved. 
To assess the association between change in eGFR during hospital stay and outcomes 
after hospital discharge, percentage change in eGFR during hospital stay ((eGFRdischarge-
eGFRadmission)/eGFRadmission)×100 was categorized into the following categories: change 
within 5% (reference), 5-20% decline, >20% decline, 5-20% increase and >20% [13]. 
Association was examined for patients who were alive at discharge (N=8,021). This 
association was additionally adjusted for length of hospital stay. For recurrent stroke and 
incident myocardial infarction, analysis was performed for patients who did not develop these 
outcomes during hospital stay (N=7,928 and N=7,937, respectively).  
Multiple imputation was performed by chained equations with 10 iterations to impute 
missing data (previous stroke (n=253), stroke severity (n=631) and pre-stroke modified 
Rankin score (n=674)) [14].  
A two tailed p-value of <0.05 was considered significant. All analyses were 
performed using Stata/SE version 14.0. 
Additional analyses 
First, we tested for interaction and presented results by stratifying according to two major 
high risk groups including diabetes and hypertension status (no/yes). Second, we examined 
association between eGFR change and outcomes when adjusting for baseline eGFR. Third, 
for change in eGFR during hospital stay, we examined association when using different cut-
off of change in eGFR (i.e. 5% (reference), 5-25% decline, >25% decline, 5-25% increase 
and >25% increase). Finally, because ischemic stroke and hemorrhagic stroke can have 
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Results 
Baseline characteristics 
Table 1 shows characteristics of sample population presented according to eGFR levels. 
Median duration of hospital stay was 8 days (inter-quartile interval 4-18 days). The mean 
eGFR was 63.7±22.1 mL/min/1.73 m
2
. Low levels of eGFR were more prevalent in patients 
aged ≥65 years compared to patients aged <65 years. A similar pattern was observed for 
females and those with ischemic stroke.  
Clinical Outcomes by eGFR Levels  
Incidences of clinical outcomes assessed across eGFR categories are shown in Table 2. In 
general, incidence of adverse outcomes was higher in patients with eGFR <90 
mL/min/1.73m
2
. However, in the case of recurrent stroke, the incidence tended to have an 
inverse ‘U’ shaped distribution across eGFR categories. 
Association between eGFR and adverse outcomes 
In the age and sex adjusted model, compared to eGFR level of ≥90 mL/min/1.73 m
2
, lower 
levels of eGFR (<15, 15-29 and 30-44 mL/min/1.73 m
2
) were associated with increased risks 
of all clinical outcomes, including all-cause mortality, incident myocardial infarction, 
prolonged hospital stay and post stroke disability but not with recurrent stroke. In the 
multivariable adjusted models, these associations remained statistically significant. Similar to 
overall risk of mortality, generally lower levels of eGFR (<15, 15-29 and 30-44 
mL/min/1.73m
2
) were associated with increased risk of <30, 30-365 or over 365-day 
mortality (Table 3). 
  The association between clinical outcomes and eGFR categories stratified by 10 
mL/min/1.73 m
2
 showed that, compared to eGFR category of 90-99 mL/min/1.73m
2
, risk of 












This article is protected by copyright. All rights reserved. 
risk also appeared to be high in eGFR category of ≥109 mL/min/1.73m
2
. A similar trend in 
associations was observed for the composite end point, prolonged hospital stay and stroke 
disability at discharge (Figure 1).  
 Regarding change in eGFR during hospital stay, greater than 5% decline or increase 
in eGFR during hospital stay, was associated with an increased risk of all-cause mortality, 
and stroke disability at discharge. For myocardial infarction, >20% decline or increase in 
eGFR tended to be associated with increased risk. No statistically significant association was 
observed for recurrent stroke (Table 4). 
Additional analyses 
No statistical interaction was observed for diabetes and hypertension status (no/yes) for any 
of the outcomes (eTable 1-eTable 4). Association with outcomes was essentially similar to 
our main results when adjusting for eGFR at admission for this predictor (eTable 5) and using 
different cut-off of eGFR change (eTable 6). There were a total of 8,942 cases of ischemic 
stroke and 1,387 cases of hemorrhagic stroke. When analyzing data by stroke type, results 
were essentially similar to overall results except that there were not sufficient number of 
events for myocardial infarction in hemorrhagic stroke (eTables 7-10).  
 
Discussion 
In this large unselected prospective cohort of stroke patients, low eGFR levels of <15, 15-29 
and 30-44 mL/min/1.73m
2
 which clinically correspond to very severely (or kidney failure), 
severely or moderate to severely impaired kidney function, respectively, were associated with 
increased risk of poor clinical outcomes. This association was particularly strong for the risk 
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at discharge. In addition, ≥5% change in eGFR during hospital stay was associated with 
increased risk of adverse clinical outcomes except recurrent stroke.  
 Whilst a number of previous studies have examined the association between eGFR 
and risk of adverse clinical outcomes in stroke patients [3-5], our study expands current 
knowledge in a number of ways. Firstly, our study provides risk (both absolute and relative) 
of poor outcomes across all clinically relevant categories of eGFR which is critically 
important for clinical decision making. Secondly, to our knowledge, this is the first study to 
examine the association between change in eGFR during hospital stay and relevant and 
important clinical outcomes, and demonstrates that both significant increase and decline in 
eGFR during hospital stay may indicate poor prognosis in stroke patients.  
 While our findings show higher risk of poor outcomes for moderately to severely 
reduced eGFR but lower risk for mildly and mild to moderately decreased eGFR. Similar 
findings has been observed previously in general population cohorts [15,16]. These findings 
are likely due to severity of illness of patients in eGFR category of ≥90 mL/min/1.73m
2
. Due 
to loss of muscle mass in chronically ill patients, serum creatinine based eGFR may over-
estimate their kidney function. Thus, patients in creatinine based eGFR category of ≥90 
mL/min/1.73m
2 
may actually be at increased risk of poor clinical outcomes. This was 
apparent when association was examined between eGFR divided into groups spanning 10 
mL/min/1.73 m
2
 and outcomes.  
 Another finding of our study was that change (≥5%) in eGFR during hospital stay also 
predicted prognosis in stroke patients. Importantly, this association was independent of eGFR 
at admission. Decline in kidney function during hospital stay likely signifies deteriorating 
kidney function and consequently poor prognosis in these patients. It could also be because of 
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Withdrawal of antihypertensive agents is commonly done in the patients presenting with 
acute stroke [17]. Causes of increased risk for poor prognosis with increase in eGFR during 
hospital stay is unclear to us. It is possible that an increase in eGFR during hospital stay may 
not indicate true improvement in kidney function but may indicate deterioration of their 
physical condition which may have resulted in overestimation of their kidney function at 
second measurement closer to discharge [15,16].  
In this study we did not find a statistically significant association between low eGFR 
with recurrent stroke. This could be due to fewer number of recurrent stroke events in low 
eGFR categories. Moreover, higher short-term mortality may be obscuring the true 
relationship. Indeed, previous studies that observed this association either examined fatal and 
non-fatal re-occupant stroke together [3] or found association with stroke reoccurrence only 
in a composite outcome analysis [4]. Similar to our study, one study that examined non-fatal 
stroke recurrence found no association between low eGFR and stroke recurrence [18]. Lack 
of association between eGFR and stroke has also been observed in other high risk populations 
such as those with chronic kidney disease [19]. 
Our findings suggest that in stroke management, eGFR may be used as an additional 
early biomarker to identify high risk patients for complications. Our findings of independent 
association between change in eGFR during hospital stay and clinical outcomes provide an 
additional tool in prediction of prognosis in stroke patients. Since this association was also 
independent of eGFR at baseline, a second assessment of kidney function at/around discharge 
may be valuable in predicting longer term prognosis. Our findings also suggest that there 
should be caution in interpreting creatinine based high eGFR values since high eGFR may 
not always mean better kidney function and thus a better prognosis, particularly in 
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The present study has some limitations. First, eGFR was estimated using serum 
creatinine which is influenced by muscle mass [20], and thus may not provide the most 
reliable assessment of kidney function, particularly in chronically ill patients where Cystatin 
C may be used for more accurate assessment of kidney function [21]. However, in routine 
clinical practice serum creatinine still remains the main biomarker for assessment of kidney 
function and thus highlights the usefulness of our findings in routine patient care. Second, 
data was not available on smoking and alcohol intake, and body mass index. However, we 
adjusted for major determinants of eGFR and poor outcomes including diabetes, hypertension 
and CVDs which are also linked to lifestyle factors listed above and thus likely have reduced 
confounding related to the unmeasured lifestyle factors.  
This study also has a number of strengths. Our large sample population allowed us to 
conduct a rigorous analysis, so as to examine the size and shape of the association between 
eGFR and poor clinical outcomes across all clinically relevant categories of eGFR. In 
addition, we were also able to examine the consistency of these association across various 
sub groups. Furthermore, the current study included a second measurement of serum 
creatinine, which allowed analysis of the importance of change in eGFR during hospital stay 
in stroke prognosis.  
In summary, stroke patients with low levels of eGFR at hospital admission 
(particularly in categories of <15, 15-29 and 30-44 mL/min/1.73m
2
) and greater than 5% 
change in eGFR during hospital stay (decline or increase) were associated with increased risk 
of poor clinical outcomes of all-cause mortality, myocardial infarction, prolonged hospital 
stay and stroke disability at discharge. These findings emphasize the importance of assessing 











This article is protected by copyright. All rights reserved. 
Acknowledgements 
We thank the data team of the Norfolk and Norwich University Hospital Stroke Services. 
Funding 
Authors did not receive specific funding for this project. 
Disclosure 
None. 
Conflicts of interests 
None. 
Contributors 
Study conception, literature search, data analysis, and drafting the manuscript: PV; Data 
acquisition and data management: JHBS; Supervisor or mentorship: PKM, AKM, KMB and 
JFP; All authors contributed in interpretation of results. Each author contributed important 










This article is protected by copyright. All rights reserved. 
References: 
1. Yahalom G, Schwartz R, Schwammenthal Y, et al. Chronic kidney disease and 
clinical outcome in patients with acute stroke. Stroke. 2009;40(4):1296-1303.  
2. Zheng D, Sato S, Arima H, et al. Estimated GFR and the Effect of Intensive Blood 
Pressure Lowering After Acute Intracerebral Hemorrhage. Am J Kidney Dis. 
2016;68(1):94-102.  
3. Luo Y, Wang X, Matsushita K, et al. Associations between estimated glomerular 
filtration rate and stroke outcomes in diabetic versus nondiabetic patients. Stroke. 
2014;45(10):2887-2893. 
4. Yang J, Arima H, Zhou J, et al. Effects of low estimated glomerular filtration rate on 
outcomes after stroke: a hospital-based stroke registry in China. Eur J Neurol. 
2014;21(8):1143-1145.  
5. Luo Y, Wang X, Wang Y, et al. Association of glomerular filtration rate with 
outcomes of acute stroke in type 2 diabetic patients: results from the China National 
Stroke Registry. Diabetes Care. 2014;37(1):173-179.  
6. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of 
chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 
2011;80(1):17-28. 
7. Kwok CS, Skinner J, Metcalf AK, Potter JF, Myint PK. Prior antiplatelet or 
anticoagulant therapy and mortality in stroke. Heart. 2012;98:712-717. 
8. Bettencourt-Silva J, De La Iglesia B, Donell S, Rayward-Smith V. On creating a 
patient-centric database from multiple hospital information systems. Methods Inf Med 
2012; 51:210–220. 
9. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular 










This article is protected by copyright. All rights reserved. 
10. United Kingdom Census 2011. Office of National Statistics. 
http://www.ons.gov.uk/census/2011census (Accessed May 20, 2018) 
11. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischemic 
attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 
1991;54:1044e54. 
12. Fine J, Gray R. A Proportional Hazards Model for the Subdistribution of a Competing 
Risk. Journal of the American Statistical Association 1999, 94(446), 496-509. 
13. Turin TC, Coresh J, Tonelli M, et al. Change in the estimated glomerular filtration 
rate over time and risk of all-cause mortality. Kidney Int. 2013;83(4):684-691.  
14. Royston P, White I. Multiple Imputation by Chained Equations (MICE): 
Implementation in Stata. Journal of Statistical Software 2011, 45(4), 1 - 20. 
15. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, et al. 
Association of estimated glomerular filtration rate and albuminuria with all-
cause and cardiovascular mortality in general population cohorts: a collaborative 
meta-analysis. Lancet. 2010 ;375(9731):2073-81. 
16. Naimark DM, Grams ME, Matsushita K. et al. Past Decline Versus Current eGFR and 
Subsequent Mortality Risk. J Am Soc Nephrol. 2016;27(8):2456-66.  
17. Qureshi AI. Acute hypertensive response in patients with stroke: pathophysiology and 
management. Circulation. 2008;118(2):176-87.  
18. Miyagi T, Koga M, Yamagami H, et al. Reduced estimated glomerular filtration rate 
affects outcomes 3 months after intracerebral hemorrhage: the stroke acute 
management with urgent risk-factor assessment and improvement-intracerebral 










This article is protected by copyright. All rights reserved. 
19. Sandsmark DK, Messé SR, Zhang X. et al. Proteinuria, but Not eGFR, Predicts Stroke 
Risk in Chronic Kidney Disease: Chronic Renal Insufficiency Cohort Study. Stroke. 
2015;46(8):2075-80. 
20. Vart P, Grams ME. Measuring and Assessing Kidney Function. Semin Nephrol. 
2016;36(4):262-272. 
21. Traynor J, Mactier R, Geddes CC, Fox JG. How to measure renal function in clinical 




Figure 1: HRs (95% CIs) for: A) all-cause mortality; B) combined end point, and ORs 
(95% CIs) for; C) prolonged hospital stay and; D) stroke disability at discharge, 
according to the level of eGFR categorized by 10 mL/min/1.73 m
2
 difference, with eGFR 
of 90-99 mL/min/1.73 m
2
 serving as the reference group 
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Table 1: Characteristics of sample population by level of estimated glomerular filtration rate 


















Age (years)  77.8 ± 11.9  59.7 ± 12.8 77.1 ± 10.4 81.8 ± 8.9 84.2 ± 7.9 83.8 ± 8.5 78.5 ± 12.1 <0.001 
Sex (male)  47.5 (4,902)  62.8 (731) 48.9 (2,425) 42.6 (938) 38.5 (556) 40.8 (247) 50.3 (79) <0.001 
History of stroke*, %(n)  24.6 (2,474)  16.3 (173) 23.2 (1,100) 26.8 (572) 28.2 (394) 33.4 (196) 26.5 (39) <0.001 
Stroke type (Ischemic), %(n)  86.6 (8,942)  80.4 (889) 84.9 (4,135) 88.3 (1,923) 90.7 (1,294) 93.3 (556) 92.4 (145) <0.001 
OSCP classification*          <0.001 
-TACS  20.9 (2,028)  14.5 (149) 19.7 (895) 22.8 (470) 23.8 (322) 27.5 (157) 23.8 (35)  
-PACS  33.2 (3,215)  29.1 (299) 33.1 (1,503) 34.9 (720) 35.3 (478) 31.2 (178) 25.2 (37)  
-LACS  22.6 (2,188)  24.7 (253) 23.6 (1,072) 21.9 (452) 20.9 (284) 18.3 (104) 15.7 (23)  
-POCS  16.8 (1,629)  24.3 (249) 17.6 (799) 14.3 (294) 13.4 (181) 14.4 (82) 16.3 (24)  
-Other  6.6 (638)  7.3 (76) 5.9 (269) 6.1 (127) 6.5 (89) 8.5 (49) 19.1 (28)  
Pre-stroke mRS*           
-0  63.3 (6,113)  76.7 (779) 67.8 (3,121) 60.7 (1,236) 51.9 (677) 42.1 (230) 39.7 (50) <0.001 
-1  12.1 (1,167)  9.9 (103) 12.3 (566) 11.2 (228) 12.8 (167) 15.4 (84) 15.1 (19)  
-2  8.2 (794)  5.7 (59) 7.4 (341) 8.9 (182) 10.1 (131) 12.1 (66) 11.9 (15)  
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-4  4.8 (466)  2.1 (22) 3.7 (171) 4.9 (100) 8.3 (108) 10.3 (56) 7.1 (9)  
-5  2.0 (197)  1.3 (13) 1.4 (63) 2.9 (58) 2.9 (38) 2.4 (13) 9.5 (12)  
Diabetes, %(n)  14.6 (1,505)  11.6 (128) 11.6 (564) 13.4 (291) 15.3 (218) 21.1 (126) 28.0 (44) <0.001 
Hypertension, %(n)  51.8 (5,354)  32.0 (354) 46.2 (2,249) 48.9 (1,064) 52.6 (750) 59.4 (354) 59.9 (94) <0.001 
Dyslipidemia, %(n)  10.3 (1,062)  11.5 (127) 9.8 (478) 8.5 (186) 7.6 (109) 8.1 (48) 9.6 (15) 0.059 
Coronary heart disease, %(n)  23.4 (2,417)  9.5 (105) 18.7 (912) 23.3 (507) 29.4 (419) 35.2 (210) 37.6 (59) <0.001 
Heart failure, %(n)  11.8 (1,219)  3.4 (38) 7.5 (365) 12.4 (271) 17.8 (254) 28.0 (167) 27.4 (43) <0.001 
Atrial fibrillation, %(n)  26.9 (2,786)  8.1 (89) 22.6 (1,098) 29.2 (635) 32.4 (463) 36.1 (215) 27.4 (43) <0.001 
Length of hospital stay (days)  8 (4 – 18)  6 (2 – 12) 7 (3 – 16) 10 (4 – 20) 11 (4 – 21) 11 (5 – 23) 8 (3 – 18) <0.001 
 
Abbreviations: OSCP=Oxfordshire Community Stroke Project; TACS: total anterior circulation stroke; PACS: partial anterior circulation stroke; LACS: lacunar stroke; POCS: posterior 
circulation stroke; mRS=modified Rankin score 
Continuous variables with normal distribution are presented as mean ± standard deviation and non-normal distribution are presented as median (interquartile interval); categorical variables are 
presented as percentages (n) 
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Table 2: Clinical outcomes in patients with stroke during follow-up according to eGFR level 
 

















All-cause mortality         
- % (n)  27.0 (299) 45.8 (2229) 57.5 (1251) 69.7 (995) 80.5 (480) 86.6 (136) 
- incidence rate (1000-person years)  71 (63 – 80) 143 (138 – 149) 196 (186 – 207) 335 (315 – 357) 563 (514 – 615) 760 (642 – 899) 
Recurrent stroke        
- % (n)  7.1 (79) 8.7 (423) 8.8 (192) 8.7 (124) 5.9 (35) 4.5 (7) 
- incidence rate (1000-person years)  20 (16 – 24) 28 (26 – 31) 32 (28 – 37) 45 (38 – 53) 43 (31 – 60) 41 (19 – 85) 
Myocardial infarction        
- % (n)  1.1 (12) 1.9 (95) 2.5 (55) 2.4 (34) 3.0 (18) 3.2 (5) 
- incidence rate (1000-person years)  3.3 (1.9 – 5.6) 7.4 (6.1 – 8.9) 9.9 (7.7 – 12.6) 13 (9 – 18) 24 (15– 37) 28 (12 – 68) 
Prolonged hospital stay, % (n)        
- above median (>8 days)  35.0 (387) 45.8 (2,227) 54.4 (1,182) 57.9 (827) 57.9 (345) 49.0 (77) 
Stroke disability*
Ϯ
, %(n)         
- Mild (0-1)  46.9 (379) 32.4 (1,074) 22.7 (304) 18.6 (172) 12.0 (48) 14.2 (18) 
- Moderate (2-3)  21.6 (175) 23.8 (790) 22.1 (296) 17.8 (165) 14.8 (59) 14.9 (19) 
- Severe (4-6)  31.5 (255)  43.8 (1,454) 55.3 (742) 63.6 (589) 73.2 (292) 70.9 (90) 
 
Abbreviation: eGFR=estimated glomerular filtration rate 
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Table 3: Association of eGFR at admission with clinical outcomes during follow-up in patients with stroke  

















  Hazard ratio (95% Confidence interval)
Ϯ
 
All-cause mortality        
-Model 1  Ref. 0.81 (0.71 – 0.93) 0.87 (0.75 – 1.00) 1.18 (1.02 – 1.37) 1.56 (1.33 – 1.84) 2.64 (2.14 – 3.26) 
-Model 2  Ref. 0.91 (0.80 – 1.04) 0.96 (0.83 – 1.11) 1.23 (1.06 – 1.43) 1.54 (1.31 – 1.82) 2.38 (1.91 – 2.97) 
   <30 day        
   -Model 1  Ref. 0.66 (0.55 – 0.80) 0.69 (0.56 – 0.84) 0.84 (0.67 – 1.04) 1.19 (0.95 – 1.51) 2.15 (1.61 – 2.87) 
   -Model 2  Ref. 0.77 (0.64 – 0.94) 0.80 (0.64 – 0.98) 1.00 (0.81 – 1.25) 1.26 (0.99 – 1.60) 2.19 (1.62 – 2.96) 
   30-365 day        
   -Model 1  Ref. 0.74 (0.57 – 0.96) 0.82 (0.62 – 1.08) 1.08 (0.81 – 1.43) 1.53 (1.13 – 2.08) 2.65 (1.75 – 4.00) 
   -Model 2  Ref. 0.81 (0.63 – 1.05) 0.87 (0.66 – 1.15) 1.13 (0.85 – 1.51) 1.43 (1.05 – 1.96) 2.47 (1.63 – 3.75) 
   Over 365 day        
   -Model 1  Ref. 1.19 (0.92 – 1.54) 1.29 (0.98 – 1.69) 1.71 (1.28 – 2.27) 2.42 (1.76 – 3.34) 3.45 (2.16 – 5.52) 
   -Model 2  Ref. 1.21 (0.94 – 1.57) 1.27 (0.97 – 1.68) 1.67 (1.25 – 2.23) 2.10 (1.51 – 2.91) 2.64 (1.63 – 4.28) 
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Abbreviation: eGFR=estimated glomerular filtration rate. Missing information was handled with multiple imputation. 
Ϯ
For recurrent stroke and myocardial infarction it is sub-distribution hazard ratio from competing risk regression analysis  
*N=8,054, as patients who were dead at discharge were excluded (n=2,275) 
Model 1: Age and sex 
Model 2: Model 1 + history of stroke, stroke type, pre-stroke modified Rankin score, stroke severity, diabetes, hypertension, dyslipidemia, atrial fibrillation, heart failure, 




-Model 1  Ref. 1.11 (0.85 – 1.44) 1.13 (0.83 – 1.53) 1.43 (1.03 – 2.00) 1.25 (0.82 – 1.92) 1.23 (0.55 – 2.74) 
-Model 2  Ref. 1.05 (0.81 – 1.38) 1.06 (0.77 – 1.43) 1.33 (0.95 – 1.87) 1.14 (0.74 – 1.77) 1.21 (0.54 – 2.69) 
Myocardial infarction        
-Model 1  Ref. 1.46 (0.81 – 2.63) 1.74 (0.91 – 3.32) 2.10 (1.05 – 4.21) 3.60 (1.70 – 7.63) 4.74 (1.65 – 13.65) 
-Model 2  Ref. 1.33 (0.74 – 2.40) 1.56 (0.82 – 2.97) 1.82 (0.91 – 3.63) 2.96 (1.37 – 6.39) 4.06 (1.40 – 11.75) 
  Odds ratio (95% Confidence interval) 
Prolonged hospital stay*    
- Model 1  Ref. 0.88 (0.75 – 1.04) 1.14 (0.94 – 1.37) 1.35 (1.09 – 1.67) 1.63 (1.23 – 2.15) 2.12 (1.28 – 3.51) 
- Model 2  Ref. 0.95 (0.81 – 1.13) 1.19 (0.97 – 1.49) 1.44 (1.15 – 1.80) 1.60 (1.20 – 2.13) 1.99 (1.19 – 3.35) 
Stroke disability        
- Model 1  Ref. 0.84 (0.74 – 0.97) 1.03 (0.88 – 1.21) 1.24 (1.03 – 1.48) 1.94 (1.56 – 2.41) 3.73 (2.57 – 5.40) 
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Table 4: Association of change in eGFR during hospital stay with clinical outcomes in 
patients with stroke  
  Change in eGFR during hospital stay 

















 484 1,296 3,721 1,263 1,257 
-Events, %(n)  52.7 (255) 38.0 (493) 27.9 (1,041) 46.5 (587) 56.2 (706) 
-Model 1  1.52 (1.32 – 
1.74) 
1.17 (1.05 – 
1.30) 
Ref. 1.40 (1.27 – 
1.56) 
1.58 (1.43 – 
1.76) 
-Model 2  1.56 (1.36 – 
1.79) 
1.17 (1.05 – 
1.30) 
Ref. 1.47 (1.32 – 
1.62) 




 483 1,292 3,637 1,260 1,256 
-Events, %(n)  13.2 (64) 10.5 (135) 11.3 (412) 10.9 (138) 7.4 (93) 
-Model 1  1.11 (0.85 – 
1.45) 
0.85 (0.70 – 
1.03) 
Ref. 0.98 (0.80 – 
1.19) 
0.69 (0.55 – 
0.87) 
-Model 2  1.08 (0.82 – 
1.41) 
0.83 (0.69 – 
1.02) 
Ref. 0.97 (0.80 – 
1.18) 




 483 1,293 3,643 1,261 1,257 
-Events, %(n)  4.6 (22) 2.8 (36) 2.9 (107) 2.6 (33) 3.1 (39) 
-Model 1  1.68 (1.10 – 
2.57) 
0.91 (0.63 – 
1.32) 
Ref. 0.93 (0.63 – 
1.36) 
1.22 (0.85 – 
1.74) 
-Model 2  1.66 (1.08 – 
2.54) 
0.92 (0.64 – 
1.34) 
Ref. 0.98 (0.67 – 
1.45) 
1.34 (0.93 – 
1.93) 
  Odds ratio (95% Confidence interval) 
Stroke disability 
(N=6,921) 
 529 796 3,511 963 1,122 
-Events (severe), 
%(n) 
 68.1 (360) 37.6 (299) 40.7 (1,430) 53.4 (514) 72.9 (819) 
-Model 1  2.06 (1.62 – 
2.61) 
1.47 (1.26 – 
1.71) 
Ref. 2.79 (2.39 – 
3.26) 
4.89 (4.13 – 
5.78) 
-Model 2  1.93 (1.52 – 
2.46) 
1.38 (1.18 – 
1.61) 
Ref. 2.54 (2.18 – 
2.97) 
4.14 (3.39 – 
4.91) 
Abbreviation: eGFR=estimated glomerular filtration rate. Missing information was handled with multiple 
imputation 
*
sub-distribution hazard ratios for recurrent stroke and myocardial infarction from competing risk regression 
analysis, 
Ϯ
excluded patients who were dead at discharge 
Model 1: Age, sex and length of hospital stay 
Model 2: Model 1 + history of stroke, stroke type, pre-stroke modified Rankin score, stroke severity, diabetes, 
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